ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Appili Therapeutics Inc

Appili Therapeutics Inc (APLI)

0.035
0.005
(16.67%)
Closed 21 November 8:12AM

Real-time discussions and trading ideas: Trade with confidence with our powerful platform.

Key stats and details

Current Price
0.035
Bid
0.03
Offer
0.035
Volume
90,000
0.035 Day's Range 0.035
0.025 52 Week Range 0.06
Market Cap
Previous Close
0.03
Open
0.035
Last Trade
90000
@
0.035
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
108,760
Shares Outstanding
121,266,000
Dividend Yield
-
PE Ratio
-0.96
Earnings Per Share (EPS)
-0.03
Revenue
6.69M
Net Profit
-3.78M

About Appili Therapeutics Inc

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Halifax, Nova Scotia, Can
Founded
-
Appili Therapeutics Inc is listed in the Pharmaceutical Preparations sector of the Toronto Stock Exchange with ticker APLI. The last closing price for Appili Therapeutics was $0.03. Over the last year, Appili Therapeutics shares have traded in a share price range of $ 0.025 to $ 0.06.

Appili Therapeutics currently has 121,266,000 shares in issue. The market capitalisation of Appili Therapeutics is $3.64 million. Appili Therapeutics has a price to earnings ratio (PE ratio) of -0.96.

APLI Latest News

Appili Therapeutics Announces Receipt of Final Court Order for Arrangement with Aditxt, Inc.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Court’s approval allows transaction with Aditxt to proceed, subject to other closing conditions...

Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2025

Overwhelming shareholder support in favour of take-private transaction with Aditxt Studies presented at IDWeek 2024™ demonstrate ATI-1701 provides full protection against lethal tularemia in...

Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares

Shelf utilization inclusive of the ELOC and ATM, will be suspended during the stale period beginning Monday, November 11, 2024 Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social...

Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Results of Special Meeting of Shareholders

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Appili Therapeutics Inc. (TSX: APLI;...

Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, announced today that its acquisition target, Evofem...

Biopharma Bucking Market Trends on Positive FDA Feedback

This firm’s treatment for a disfiguring skin infection has demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies, and shares are holding their own despite today's To...

Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today shared an important milestone for its target...

Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission

Demonstrated safety and efficacy across multiple Phase 2 and Phase 3 studies Appili provides update on Aditxt transaction and encourages shareholders to vote their shares as soon as possible for...

Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time

Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), a social innovation platform dedicated to accelerating promising health innovations, today announced the hosting of an update and Q&A...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1000.0350.0350.032799720.03219933CS
4-0.01-22.22222222220.0450.0450.031559020.03413815CS
12000.0350.0450.0251087600.03286361CS
26-0.005-12.50.040.050.0251070720.03572715CS
52000.0350.060.0251276070.03715185CS
156-0.155-81.57894736840.190.190.0251701310.0667712CS
260-1.095-96.90265486731.131.60.0251657400.27304194CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
SLSSolaris Resources Inc
$ 4.24
(25.44%)
1.37M
FLNTFlint Corporation
$ 0.03
(20.00%)
14k
CNECanacol Energy Ltd
$ 3.98
(16.72%)
144.87k
APLIAppili Therapeutics Inc
$ 0.035
(16.67%)
90k
KLSKelso Technologies Inc
$ 0.145
(16.00%)
40k
VRTSVertiqal Studios Corporation
$ 0.01
(-33.33%)
33.13k
APSAptose Biosciences Inc
$ 0.375
(-25.00%)
218.74k
LEVLion Electric Company
$ 0.27
(-19.40%)
1.42M
SGLDSabre Gold Mines Corp
$ 0.20
(-14.89%)
124.25k
DIAMStar Diamond Corporation
$ 0.03
(-14.29%)
28.44k
ENBEnbridge Inc
$ 59.82
(-0.22%)
10.8M
CNQCanadian Natural Resources Ltd
$ 47.21
(0.36%)
10.35M
GWOGreat West Lifeco Inc
$ 49.69
(0.26%)
6.5M
MFCManulife Financial Corporation
$ 45.01
(-1.10%)
6.47M
SUSuncor Energy Inc
$ 57.07
(-0.24%)
5.82M

APLI Discussion

View Posts
BurgerKing82 BurgerKing82 3 weeks ago
Looks interesting
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
JUST THE BEGINNING HERE....8C BREAK SENDS THIS BIG TIME
👍️ 1
TrendTrade2016 TrendTrade2016 1 year ago
ONLY ONE?
👍️0
DTGoody DTGoody 1 year ago
Congratulations you actually got one ticker right out of hundreds. Great Job! LOL
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
BOOM...BIG VOLME OUT OF THE GATE
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
DUMMY
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
FDA!!!!!!
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
The global metronidazole market was valued at USD 1.5 billion in 2018 and is projected to reach USD 2.2 billion by 2030, growing at a CAGR of 3% during the forecast period from 2021-2030. The market for metronidazole tablets segment accounted for the largest share in 2018 with over 50% share followed by metronidazole injection segment with over 30%. The demand for metronidazole tablets segment will continue to grow due to its high usage in treatment of various diseases such as bacterial vaginosis, trichomoniasis, and amebiasis among others which are expected to drive growth during the forecast period from 2021-2030.
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
The global Metronidazole market size is estimated to be worth US$ 113 million in 2021 and is forecast to a readjusted size of US$ 109.1 million by 2028 with a CAGR of -0.5% during the forecast period 2022-2030.
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
Metronidazole is a widely used frontline oral treatment with over 10 million prescriptions written in the United States every year to help treat parasitic and anaerobic bacterial infections. The current tablet form of metronidazole is the only approved oral form on the U.S. market, but its bitter taste and lack of appropriate dosage forms for patients with difficulty swallowing often presents treatment compliance challenges
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
FDA DECISION NEXT WEEK. LETS HOPE IT HAPPENS!!
👍️0
shurtha2000 shurtha2000 1 year ago
Huge wall@04 676,134 shares
👍️0
oldstocks oldstocks 1 year ago
Yes but the investment was for the good. Through Appili’s unique approach to drug development, we have created a pipeline containing a deliberate mix of close-to-market opportunities that have the potential to provide near-term value with cutting-edge programs that we believe have the potential to transform how we treat many infectious diseases, addressing significant unmet medical needs in patient care.

This approach allows Appili to seek productive collaborations with industry partners and federal government agencies whose objectives align with ours, while pursuing non-dilutive funding sources specifically earmarked for infectious diseases development programs.
👍️ 1
DTGoody DTGoody 1 year ago
APLIF as of Year ended March of 2022 The company lost 25 million Dollars or .38 cents per share. Then as of Year ending March of 2023 they lost another 9.2 million Dollars or .08 cents per share. You Were Warned! Don't Be Schooled:

https://www.otcmarkets.com/otcapi/company/financial-report/375623/content
👍️0
TrendTrade2016 TrendTrade2016 1 year ago
APLIF...NEXT BIO DEFENSE BEAST OUT OF HALIFAX...
👍️0

Your Recent History

Delayed Upgrade Clock